Key Highlights
- Citius Pharmaceuticals shares tumbled 26% to end the day at $0.56.
- The company posted a GAAP net loss of $0.34 per share, $0.09 wider than anticipated.
- Revenue of $1.5 million fell $8.27 million short of consensus.
- The company's cash balance stood at $17.0 million as it navigates the initial commercial launch of LYMPHIR.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) shares tumbled 26% to end the day at $0.56 after the company reported third-quarter financial results that missed the mark, posting a GAAP net loss of $0.34 per share, which was $0.09 wider than anticipated.
What Happened
The company's Revenue of $1.5 million fell $8.27 million short of consensus. With a cash balance of $17.0 million, the company faces continued funding needs while navigating the initial commercial launch phase for LYMPHIR.
Market Reaction
Shares tumbled sharply as investors focused on the scale of both the Earnings and revenue misses, alongside the company's continued funding needs as it works through the early stages of its commercial launch.
Outlook
Continued progress on the commercial launch of LYMPHIR, weighed against Citius Pharmaceuticals' $17.0 million cash position and ongoing funding needs, is likely to remain the key Factor shaping sentiment toward the stock going forward.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.